It is estimated that more than 30 million people in the United States and Europe have a food allergy, and more than five million people in the United States and Europe have peanut allergy, including more than two million children. Bouyed by success in earlier rounds of FDA testing, Aimmune Therapeutics, Inc. (NADSAQ: AIMT) announced earlier today that it has enrolled the first patient in the pivotal Phase 3 PALISADE trial of its lead product candidate, AR101 for the treatment of peanut allergy....
↧